# Epigenetic Reprogramming in Relapse/Refractory AML

> **NCT03263936** · PHASE1 · COMPLETED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 37 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Vorinostat
- **DRUG:** Filgrastim (G-CSF)
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03263936
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-11
- **Primary completion:** 2020-07-09
- **Final completion:** 2022-02-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263936, "Epigenetic Reprogramming in Relapse/Refractory AML". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03263936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*